Your browser is no longer supported. Please, upgrade your browser.
Settings
GWPH GW Pharmaceuticals plc daily Stock Chart
GWPH [NASD]
GW Pharmaceuticals plc
Index- P/E123.93 EPS (ttm)1.03 Insider Own1.12% Shs Outstand31.15M Perf Week2.03%
Market Cap4.00B Forward P/E37.38 EPS next Y3.42 Insider Trans-87.82% Shs Float30.61M Perf Month-0.18%
Income33.10M PEG- EPS next Q-0.66 Inst Own82.40% Short Float14.69% Perf Quarter32.77%
Sales392.70M P/S10.19 EPS this Y97.60% Inst Trans-0.63% Short Ratio12.91 Perf Half Y18.36%
Book/sh22.95 P/B5.57 EPS next Y237.90% ROA3.90% Target Price190.56 Perf Year-26.76%
Cash/sh16.01 P/C7.99 EPS next 5Y- ROE4.60% 52W Range67.98 - 180.75 Perf YTD22.32%
Dividend- P/FCF- EPS past 5Y19.00% ROI-15.90% 52W High-29.24% Beta1.95
Dividend %- Quick Ratio5.60 Sales past 5Y59.60% Gross Margin91.60% 52W Low88.14% ATR4.58
Employees901 Current Ratio6.50 Sales Q/Q207.70% Oper. Margin-18.90% RSI (14)55.92 Volatility2.69% 3.87%
OptionableYes Debt/Eq0.02 EPS Q/Q84.30% Profit Margin8.40% Rel Volume0.58 Prev Close128.11
ShortableYes LT Debt/Eq0.02 EarningsMay 11 AMC Payout0.00% Avg Volume348.08K Price127.90
Recom1.60 SMA202.17% SMA505.60% SMA20014.96% Volume200,265 Change-0.16%
Jun-30-20Reiterated Evercore ISI Outperform $250 → $275
Jun-01-20Resumed Oppenheimer Outperform $173 → $166
Apr-08-20Initiated Northland Capital Outperform $128
Mar-06-20Initiated Citigroup Buy $192
Oct-30-19Initiated H.C. Wainwright Buy $170
Oct-21-19Initiated Needham Buy $200
May-07-19Upgrade Oppenheimer Perform → Outperform
May-07-19Reiterated Guggenheim Buy $186 → $222
May-07-19Reiterated Cantor Fitzgerald Overweight $196 → $229
Mar-18-19Reiterated Cantor Fitzgerald Overweight $193 → $196
Jan-02-19Initiated JP Morgan Overweight $134
Nov-05-18Resumed Piper Jaffray Overweight
Sep-28-18Reiterated BofA/Merrill Buy $181 → $197
Sep-07-18Resumed Morgan Stanley Overweight
Aug-15-18Initiated Stifel Buy $181
Aug-08-18Reiterated Cantor Fitzgerald Overweight $235 → $211
Apr-19-18Reiterated Cantor Fitzgerald Overweight $192 → $205
Feb-06-18Reiterated Cantor Fitzgerald Buy $208 → $192
Dec-14-17Upgrade Goldman Neutral → Buy
Oct-06-17Resumed Goldman Neutral
Jul-09-20 06:49AM  
Jul-07-20 07:21AM  
Jun-30-20 02:07PM  
08:08AM  
07:00AM  
Jun-25-20 11:26AM  
Jun-24-20 01:00PM  
11:38AM  
08:07AM  
07:29AM  
Jun-23-20 07:01PM  
Jun-18-20 03:48PM  
02:57PM  
Jun-16-20 10:31AM  
Jun-10-20 06:19AM  
Jun-05-20 04:24PM  
10:45AM  
Jun-04-20 04:00PM  
Jun-02-20 07:00AM  
May-28-20 02:55PM  
May-24-20 12:25PM  
May-22-20 10:26AM  
May-21-20 02:59PM  
07:56AM  
May-13-20 06:19AM  
May-12-20 08:06AM  
07:02AM  
01:54AM  
01:01AM  
May-11-20 06:23PM  
05:12PM  
04:09PM  
04:00PM  
May-07-20 11:17AM  
May-06-20 06:28AM  
May-01-20 07:00AM  
Apr-28-20 10:33AM  
Apr-27-20 08:09AM  
Apr-21-20 02:04PM  
08:05AM  
Apr-07-20 11:11AM  
Apr-06-20 09:00AM  
Apr-01-20 12:20PM  
Mar-31-20 07:00AM  
Mar-24-20 04:20PM  
Mar-20-20 07:05AM  
Mar-13-20 07:00AM  
Mar-06-20 03:24PM  
Mar-02-20 01:23PM  
11:14AM  
Feb-26-20 04:20PM  
01:55PM  
09:36AM  
Feb-25-20 05:41PM  
04:01PM  
Feb-24-20 07:00AM  
Feb-20-20 05:50PM  
09:27AM  
Feb-12-20 08:11AM  
Feb-11-20 05:45PM  
Feb-10-20 08:56AM  
Feb-04-20 12:02PM  
08:13AM  
Feb-03-20 05:45PM  
07:20AM  
07:00AM  
Jan-31-20 12:35PM  
Jan-28-20 05:50PM  
02:36PM  
Jan-19-20 12:37PM  
Jan-17-20 05:50PM  
12:19PM  
Jan-16-20 12:16PM  
Jan-15-20 05:26PM  
12:25PM  
11:14AM  
Jan-14-20 09:15AM  
Jan-13-20 12:47PM  
11:38AM  
Jan-12-20 06:00PM  
Jan-08-20 04:17PM  
Jan-07-20 01:13PM  
Jan-05-20 11:24PM  
Dec-23-19 09:34AM  
Dec-20-19 12:04PM  
Dec-19-19 08:35AM  
Dec-16-19 03:55PM  
Dec-13-19 10:16AM  
Dec-11-19 11:12AM  
Dec-07-19 12:00PM  
Dec-06-19 08:02AM  
Dec-05-19 07:00AM  
Dec-01-19 09:30AM  
Nov-30-19 10:18AM  
Nov-29-19 12:12PM  
Nov-27-19 01:35PM  
Nov-26-19 04:45PM  
01:07PM  
01:07PM  
07:00AM  
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Snyder Douglas B.Chief Legal OfficerJul 06Sale10.509,804102,9420Jul 08 08:00 PM
Knappertz VolkerChief Medical OfficerJun 17Sale10.3518,000186,30059,940Jun 19 08:02 PM
Gover Justin D.Chief Executive OfficerJun 15Option Exercise0.004,1645458,129Jun 17 08:00 PM
GUY GEOFFREY W DRExecutive ChairmanMay 29Sale10.25720,0007,376,4005,501,521Jun 02 08:00 PM
Cline Darren SU.S. Chief Commercial OfficerMay 28Option Exercise0.007,35697,356May 29 08:00 PM
Knappertz VolkerChief Medical OfficerMay 18Option Exercise0.00133,620160139,092May 20 08:02 PM
Giacobello Scott M.Chief Financial OfficerMay 18Option Exercise0.00116,604140140,742May 20 08:01 PM
Giacobello Scott M.Chief Financial OfficerMar 13Buy6.807,20048,96088,224Mar 17 06:07 PM
GUY GEOFFREY W DRExecutive ChairmanMar 13Sale6.63600,0003,978,0006,221,521Mar 17 06:05 PM
Gover Justin D.Chief Executive OfficerMar 02Option Exercise0.0047,84462599,369Mar 04 06:01 PM
Snyder Douglas B.Chief Legal OfficerMar 02Sale8.322,56821,36667,296Mar 04 06:03 PM
MACKEY CATHERINE JDirectorMar 02Sale8.351,35611,32316,392Mar 04 06:04 PM
Brown CabotDirectorMar 02Sale8.243,14425,90717,088Mar 04 06:03 PM
Gover Justin D.Chief Executive OfficerMar 02Sale8.3332,856273,789566,513Mar 04 06:01 PM
Secor AliciaDirectorMar 02Sale8.341,29610,80916,440Mar 04 06:02 PM
Giacobello Scott M.Chief Financial OfficerMar 02Sale8.342,22018,51581,024Mar 04 06:00 PM
Knappertz VolkerChief Medical OfficerMar 02Sale8.323,42028,45479,392Mar 04 06:01 PM
Snyder Douglas B.Chief Legal OfficerFeb 26Sale9.173,87635,55069,864Feb 28 06:06 PM
Gover Justin D.Chief Executive OfficerFeb 26Sale9.0512,000108,558551,525Feb 28 06:02 PM
Knappertz VolkerChief Medical OfficerFeb 26Sale9.183,01227,63682,812Feb 28 06:02 PM
Giacobello Scott M.Chief Financial OfficerFeb 26Sale9.173,85235,32383,244Feb 28 06:01 PM
Gover Justin D.Chief Executive OfficerFeb 03Option Exercise0.00202,224263765,749Feb 05 05:00 PM
Gover Justin D.Chief Executive OfficerFeb 03Sale9.62202,2241,944,678563,525Feb 05 05:00 PM
GUY GEOFFREY W DRExecutive ChairmanJan 15Sale9.44900,0008,493,0006,821,521Jan 17 05:00 PM
MACKEY CATHERINE JDirectorJan 03Sale8.541,53613,11717,748Jan 07 05:00 PM
Secor AliciaDirectorJan 03Sale8.531,53613,10217,736Jan 07 05:01 PM
Brown CabotDirectorJan 03Sale8.583,57630,68220,232Jan 07 05:01 PM
Gover Justin D.Chief Executive OfficerDec 17Option Exercise0.0010,66814568,865Dec 19 05:02 PM
Gover Justin D.Chief Executive OfficerDec 17Sale9.175,34048,968563,525Dec 19 05:02 PM
GUY GEOFFREY W DRExecutive ChairmanNov 11Sale9.33420,0003,918,6007,721,521Nov 13 05:00 PM
Snyder Douglas B.Chief Legal OfficerAug 19Sale13.045,42470,72973,740Aug 21 05:30 PM
Snyder Douglas B.Chief Legal OfficerAug 12Sale13.883,75652,13379,164Aug 14 05:30 PM